LAURUSLABSNSELaurus Labs Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 23 Oct, 2025 · 15:39 IST

Laurus Labs posts strong Q2 and H1 FY26 results

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDFExplain this filing

LAURUSLABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-2.0%Reaction day
₹943.00
prior close
₹943.00
announcement price
After-mkt
timing
Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.2%-1.7% vs market
Pharmaceuticals peers, median of 154sector-0.3%-1.7% vs sector

On the reaction day the stock moved 1.7 pts less than Nifty Midcap 150 and 1.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.9
10m
-3.9
15m
-4.1
30m
-3.6
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-2.0-0.2-1.7-0.3-1.7
Next day
-0.3+0.6-0.9-0.5+0.1
2d
+1.9+0.6+1.3-0.4+2.3
3d
+1.8+1.1+0.7+0.1+1.7
4d
+2.8+1.0+1.8+0.4+2.4
5d
+1.3+0.5+0.8+0.1+1.2
1w
+4.3+0.9+3.4-0.4+4.7
15d
+8.7+2.5+6.2-1.3+10.0
1m
+4.2+0.6+3.6-3.6+7.8
2m
+15.2+1.4+13.8-4.5+19.6
3m
+5.9-3.7+9.7-12.3+18.2
UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 154Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Unaudited Q2 and H1 FY26 results showed revenue growth of 35% and 33%, respectively. Q2 revenue was Rs 1,653 crore, EBITDA was Rs 429 crore and net profit was Rs 195 crore. H1 revenue was Rs 3,223 crore, EBITDA Rs 818 crore and net profit Rs 358 crore. H1 EBITDA margin expanded 10.8 percentage points to 25.4%. The company declared an interim dividend of Rs 0.80 per share and continues investing in capacity.

Likely market impact

Strong growth, wider margins and a dividend support shareholders, though results are unaudited and future performance depends on execution and demand.